- Natera, Inc. recently reported Clinical Cancer Research data showing its Signatera molecular residual disease test helped older women with early-stage ER+/HER2- breast cancer use primary endocrine therapy instead of surgery, with testing done at baseline and then every 3–6 months.
- The study’s ability to identify patients who remained progression-free and to detect molecular signs of tumor progression before imaging highlights Signatera’s potential role in personalized treatment decisions for this population.
- We’ll now explore how this new evidence for Signatera’s use in guiding primary endocrine therapy could influence Natera’s broader investment narrative.
The latest GPUs need a type of rare earth metal called Neodymium and there are only 26 companies in the world exploring or producing it. Find the list for free.
Natera Investment Narrative Recap
To own Natera, you have to believe that molecular residual disease testing like Signatera can become a standard tool across oncology and women’s health, and that growing test volume can eventually offset today’s losses. The new breast cancer data meaningfully supports Signatera’s clinical utility, but it does not change that the biggest near term catalyst remains regulatory and reimbursement progress for oncology indications, while the primary risk is continued high spending without a clear path to sustainable profitability.
The most relevant recent announcement here is Natera’s February 2026 PMA submission for Signatera as a companion diagnostic in muscle invasive bladder cancer, supported by IMvigor011 data. Together with the new Clinical Cancer Research breast cancer publication, this reinforces how Natera is trying to anchor Signatera across multiple tumor types, which could be important for future reimbursement decisions and for justifying the company’s substantial R&D and commercial investments.
Yet alongside this clinical momentum, investors should be aware that rising regulatory scrutiny and healthcare cost controls could still...
Read the full narrative on Natera (it's free!)
Natera's narrative projects $3.8 billion revenue and $171.8 million earnings by 2029. This requires 18.4% yearly revenue growth and an earnings increase of about $380 million from -$208.2 million today.
Uncover how Natera's forecasts yield a $260.65 fair value, a 30% upside to its current price.
Exploring Other Perspectives
While this breast cancer study adds to Signatera’s promise, the most cautious analysts still project only about 14 percent annual revenue growth to roughly US$2.9 billion and no profitability by 2028, underscoring how differently you might weigh regulatory and reimbursement risks compared with more optimistic views.
Explore 6 other fair value estimates on Natera - why the stock might be worth as much as 59% more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Natera research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.
Looking For Alternative Opportunities?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com